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Abstract
Background: The underlying cause of epithelial ovarian cancer (EOC) is unknown. It has been theorized that infectious
agents could contribute to ovarian tumorigenesis.
Objective: To investigate the potential role of oncogenic viral infection in EOC, we examined the prevalence of
Epstein-Barr Virus (EBV) DNA and cytomegalovirus (CMV) DNA in EOC tissue samples.
Methods: Formalin-fixed, paraffin-imbedded (FFPE) tumor tissue samples from 198 patients included in the Danish
Pelvic Mass Study were studied: 163 with serous adenocarcinomas, 15 with endometrioid adenocarcinomas, 11 with
mucinous adenocarcinomas, and nine with clear-cell carcinomas. For controls in the EBV analysis, we used 176 tissue
samples from patients diagnosed with benign mucinous cystadenomas. EBV and CMV genotyping was performed by
real-time polymerase chain reaction with CMV and EBV CE-IVD approved kits. In-situ hybridization (ISH) was performed
on the EBV positive samples.
Results: Sufficient DNA material was obtained in 191 and 174 tissue samples from cases and controls, respectively. Ten
of 191 case samples (5.2%) and one of 174 control samples (0.5%) were positive for EBV DNA (P value = 0.011).
CMV DNA was detected in only one case sample (0.5%). ISH confirmed that three of the samples were of stromal
origin, while the remaining seven tested negative for EBV.
Conclusions: This study is the first to demonstrate a higher prevalence of EBV DNA in tissue samples from patients with
EOC than in a benign control group. However, the cellular origin of seven of the samples could not be determined by
ISH analysis. Our study did not support an association between CMV and EOC.
Keywords: Epithelial ovarian cancer, Viral carcinogenesis, Cytomegalovirus, Epstein-Barr virus
Introduction
Epithelial ovarian cancer (EOC) has a poor prognosis,
with a global 5-year age-standardized survival rate of
30–40% [1]. Patients often present with advanced-stage
disease due to the absence of effective screening methods
and the scarceness of symptoms [2]. EOC is subdivided into
serous (high-grade and low-grade adenocarcinomas), mu-
cinous, clear-cell, and endometrioid carcinomas, the serous
type being by far the most frequent [3]. Data suggest that
EOC subtypes are separate entities, characterized by dis-
tinct histopathologic, prognostic, and molecular profiles
[4–6]. Some of the subtypes may have an extra-ovarian
origin, and recently, serous tubal intraepithelial carcinomas
(STICS) have been shown to be present in the tubal fimbria
and could represent precursor lesions of serous EOC [7, 8].
Germline mutations, most notably BRCA1/2, can ac-
count for up to 20% of EOC cases [9]. Other predispos-
ing factors are nulliparity, infertility, and endometriosis,
whereas parity, contraceptive pills, hysterectomy, and
tubal ligation are known to reduce EOC risk [10, 11].
The predominant hypothesis on ovarian carcinogenesis
suggests that incessant ovulation and the continuous
cycle of ovarian rupture and inflammation causes the
release of inflammatory mediators and reactive oxygen
species that could cause mutagenic DNA damage [12].
However, our current knowledge of ovarian carcinogenesis
is deficient, compromising advances in early detection
measures and prevention.
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The female anatomy allows access to the internal geni-
tals through the genital tract. This is evident in pelvic in-
flammatory disease (PID), where an ascending infection
can cause permanent damage to the fallopian tubes and
compromise fertility [13]. Moreover, some studies have
reported an increased risk of EOC in patients with prior
PID [14, 15]. Thus, infectious agents could be involved
in ovarian carcinogenesis.
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV)
seroprevalence rates are high in the global population
[16, 17]. The viruses can establish life-long latency in
human cells and thereby evade the host immune re-
sponse [18, 19]. EBV is implicated in the development of
nasopharyngeal and gastric carcinomas as well as in a
range of lymphoproliferative disorders [20–22].
CMV contains several onco-proteins with the potential
to cause immune evasion and affect human cell cycle
progression and angiogenesis [23]. CMV is suspected to
elicit an onco-modulatory effect by sustaining and pro-
moting a tumor-friendly milieu and thus aiding cancer
progression and metastasis [24]. The virus has been de-
tected in gliomas, colorectal carcinomas, hepatocellular
carcinomas, and breast cancers [25–28].
To elucidate the potential role of EBV and CMV in
ovarian carcinogenesis, we investigated the prevalence of
both viruses in epithelial EOC tissue samples and compared
findings to those obtained in a benign control group.
Material
The tissue samples studied originated from the Danish
Pelvic Mass study, which is a continuing and national
sampling of serum and tissue samples. The inclusion cri-
terion was referral for surgery to a specialized center on
suspicion of EOC. Exclusion criteria were relapse of prior
malignant disease, previous neoadjuvant chemotherapy
(NACT), or synchronous cancer other than EOC.
Approval by the Danish National Committee on Health
Research Ethics was obtained (KF01–227/03 and KF01–
143/04, H-3-2010-022), and all patients consented orally
and in written statements prior to enrollment in the Pelvic
Mass study. The rate of acceptance was 95% among eli-
gible patients.
For the present study, formalin-fixed and paraffin-em-
bedded (FFPE) EOC tumor samples were obtained from
246 patients with EOC consecutively included from
Copenhagen University Hospital, Rigshospitalet, and
Herlev Hospital in the time span 2004–2010. After revi-
sion of the samples, 48 patients had to be excluded for
the reasons given in Fig. 1.
FFPE samples from 176 patients with benign ovarian
tumors were included as a control group. These patients
underwent surgery due to suspicion of EOC. However,
the final pathology report revealed benign mucinous
ovarian tumors in all controls. The control group was
used exclusively for the EBV analysis.
The Danish Gynecologic Cancer Database was used to
document and store patient data, while the tissue speci-
mens were sampled perioperatively and preserved in the
Danish Cancer Biobank [29].
Methods
DNA based analyses
The FFPE tissue specimens were assessed by a pathologist,
and representative areas were selected and sampled with a
2-milimeter biopsy punch.
Qiagen® Qiacube equipment was used for DNA extrac-
tion, and the concentration of DNA was subsequently
measured on Nanodrop® and diluted to 5 ng/μl.
The following DNA analyses were carried out in com-
pliance with the manufacturer’s instructions [30, 31]. For
the CMV analysis, genotyping was performed with the
Altona Realstar® CMV, CE-IVD approved kit with sensi-
tivity of 99.04% and specificity of 100%.
For the EBV analyses of the malignant samples and the
benign controls, genotyping was done with the Altona
Realstar® EBV, CE-IVD approved kit. For the detection of
EBV-specific DNA, the analytical sensitivity is 1.1 copies/
μl; 95% confidence interval (CI): [0.578–3.253 copies/μl.
The Roche®LC480 Lightcycler was used for real-time
polymerase chain reaction (PCR) analysis.
The cycling parameters were 95 °C for 10 min contin-
ued by 45 cycles at 95 °C for 15 s, 58 °C for 1 min. During
each PCR reaction, a 10-μl sample template or controls
were used. Each operation included four positive con-
trols and one negative control.
Fig. 1 Inclusion of case patients. EOC Epithelial ovarian cancer
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ISH
From the tissue samples found positive by PCR, ISH was
performed. Tissue slides of 2.5–3 /μm were used. Briefly,
after deparaffinization, sections were digested with pro-
teinase K at 37 °C for 30 min, dehydrated and dried.
Hybridization with digoxigenin-labeled probes was then
performed according to manufacturer’s instruction. BOND
ISH probes (EBER probe ASR, ready-to-use Novocastra
PB0589) were used.
An EBV-positive control, simultaneously stained by the
same method, was included.
Statistical analyses
STATA statistical software version 14.2 was used for the
statistical analysis.
Logistic regression was used to estimate odds ratios
with 95% CIs by comparing the case group to the con-
trol group. The p value was calculated using 2-sided
Fisher’s exact test, and a p value below 0.05 was consid-
ered significant.
Results
Table 1 lists the tumor histopathology, age, and Inter-
national Federation of Gynecology and Obstetrics (FIGO)
stage distribution of the 198 case patients. The median
age of the EBV controls was 55 years (range 77) and 64
years (range 58) in the case patients. No other variables
were available for the control group.
For real-time PCR analysis, seven samples were ex-
cluded due to low amounts of DNA.
Ten of the remaining 191 EOC samples were positive
for EBV DNA (5.2%) as was one (0.5%) of the controls.
EBV DNA positivity in the control group was confirmed
by in ISH and immunohistochemistry. The distribution
of EBV-positive samples along with EOC histologic
grade, subtype, and FIGO stage is given in Table 2.
The cycle threshold values ranged between 33 and 37,
indicating weak infections with a low number of viral
copies. To test the validity of the results, the analysis
was repeated in four runs with identical, positive results.
The prevalence of EBV DNA was significantly higher
in the EOC samples than in the benign ovarian tumors
(Table 3). The EBV positive samples were subsequently
tested by ISH to determine whether the signal originated
from stromal cells or invading leukocytes. For three out
of the 10 samples a positive signal originating from both
stromal cells and leukocytes was confirmed. The remaining
7 tissue samples were negative for EBV using the ISH
analysis.
CMV DNA was detected in one (0.5%) case sample
only, and due to the low prevalence, results were not
compared to a control group.
Discussion
This study is the first to report a significantly higher
prevalence of EBV in EOC tissue samples than in samples
from a benign control group of ovarian benign tumors.
The strengths of the present study were the meticu-
lous retesting of results and the structured information
on the patients in the case cohort. Another strength was
the use of consecutive sampling of case and control pa-
tients, which reduces the risk of sample selection bias.
The study also had some potential limitations. The DNA
material contained in FFPE tissue samples is prone to
Table 1 Histopathology, stage, and age of included case patients
EOC included N = 198
Age, median (range) 64 (58)
FIGO Tumor stage
Stage I, n (%) 31 (15.7%)
Stage II, n (%) 21 (10.6%)
Stage III, n (%) 120 (60.1%)
Stage IV, n (%) 26 (13.1%)
Histopathology
Serous adenocarcinoma, n (%) 163 (82.3%)
Mucinous adenocarcinoma, n (%) 11 (5.6%)
Endometrioid adenocarcinoma, n (%) 15 (7.6%)
Clear Cell carcinoma, n (%) 9 (4.5%)
EOC Epithelial ovarian cancer
FIGO International Federation of Gynecology and Obstetrics
Table 2 Characteristics of EBV-positive cases
No. Age FIGO stage Histologic grade EOC subtype
1 80 IIb 2 Serous
2 60 Ia 3 Serous
3 81 IV 3 Serous
4 52 IV 3 Serous
5 72 IIIc 3 Serous
6 75 IIIc 2 Serous
7 86 IIIc 3 Serous
8 81 IIIc 3 Serous
9 64 IIc 2 Serous
10 53 IV 3 Serous
EOC Epithelial ovarian cancer
FIGO International Federation of Gynecology and Obstetrics
Table 3 Results of EBV PCR analysis in case and control patients
EBV positive no (%) EBV negative no (%) Total no (%)
Cases 10 (5.2) 181 (94.7) 191 (100)
Controls 1 (0.5) 173 (99.4) 174 (100)
total 11 (3.0) 354 (96.9) 365 (100)
Odds ratio: 9.55, 95% Confidence interval: [1.32–417.06]
2-sided Fischer’s exact test p value = 0.011
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degradation and fragmentation, which can potentially
compromise results [32]. However, we have previously
demonstrated HPV DNA in 90% of anal cancers using a
comparable FFPE material and similar PCR-based tech-
niques [33].
Under optimal conditions, more variables should have
been available to allow for adjustment of potential con-
founding factors. Age distribution was available for both
case and control groups, and we found that the controls
were younger than the case patients (median 55 years vs.
64 years, respectively). This should not significantly in-
fluence results, as EBV seroconversion occurs already in
adolescence in the vast majority of patients [34].
Three out of ten EBV positive samples using PCR were
confirmed in a subsequent ISH analysis. EBV infected
lymphocytes is known to invade tumor tissue and thus the
findings by PCR could be a result of tissue inflammation
rather than the presence of viral gene products in tumor
cells [35]. All three positive signals originated from stro-
mal cells as well as from plasma. This is indicative that
EBV genome was in fact present in the tumor cells.
However, in seven samples, EBV positivity by PCR
could not be confirmed by ISH. The explanation could
be the amplification of the target DNA in PCR based
methods, resulting in a higher sensitivity than in ISH.
Another explanation could be that the ISH analysis
was carried out using tissue slides cut subsequently to
the original PCR tissue samples. This could influence
the results as EBV infected cells can cluster inside the
tumors, as described in more detail below [36].
Very few previous studies have examined the association
between EOC and EBV and CMV. A serologic study re-
ported a higher risk of ovarian cancer among patients with
a late debut of mononucleosis, arguing that a late debut is
a surrogate for a more severe clinical course. The same
study found that elevated IgG titers to EBV viral capsid
antigen were associated with a 5.3-fold (95% CI 1.5–18.4)
increase in EOC risk, indicating that previous EBV infec-
tion could be associated with EOC [37]. In contrast, a re-
cent serologic study reported no association between EOC
and EBV antibody levels [38]. The same was true in a
study by Khoury et al., where no evidence of EBV DNA in
419 ovarian serous cystadenocarcinomas from the Cancer
Genome Atlas was found [39].
The prevalence of CMV was very low in the present
study. This is in line with the aforementioned study that
did not find serologic evidence of CMV infection [38].
Thus, results do not support the findings in two previ-
ous small studies. One study included 24 fresh malig-
nant ovarian tissue samples and reported a prevalence of
50% by a PCR-based assay using CMV glycoprotein B
gene-specific primers [40]. The other study detected hu-
man CMV tegument protein in 80% of cases using FFPE
tissue samples from 10 patients with serous EOC [41].
The variance in the reported prevalence of CMV and
EBV could be due to a number of factors. First, EBV and
CMV seroprevalence is unevenly distributed among geo-
graphic regions [42, 43]. Second, differences in the sam-
ples studied and in the methodological approaches could
play a role. Another explanation is tumor heterogeneity
and the potential uneven distribution of infected cells.
Arbach et al. demonstrated by PCR analysis that biopsies
from the same malignant breast tumor could be EBV
DNA positive as well as negative due to clustering of
EBV-infected tumor cells [36].
Thirdly, most of the previous studies did not account
for the number of patients who received neoadjuvant
chemotherapy prior to specimen sampling. Chemotherapy
could potentially increase the number of positive results
due to reactivation of latent viral infection [41, 44]. In the
present study, patients who received NACT were ex-
cluded, which could result in the lower prevalence.
Although our findings in this study were statistically
significant, the EBV DNA prevalence was only 5% and
only three samples were confirmed by ISH. This is consid-
erably lower than the reported 80–100% prevalence of EBV
in nasopharyngeal carcinoma tissue [45]. For other poten-
tial EBV-related cancers, prevalence ranges from 6 to 95%,
with a higher incidence in Asian countries and among
males [45]. The low EBV DNA prevalence in our study
prompts caution in the interpretation of results. However, a
low prevalence does not exclude the notion of viral initi-
ation or promotion of tumorigenesis and then subsequent
clearance from the host, also described as the “hit and run”
hypothesis [46].
Moreover, inflammation is a common trait in some of
the factors suspected of predisposing to EOC, including
endometriosis, ovulation, and PID. Several studies demon-
strate the important role of inflammatory mediators, such
as interleukins and TNF alpha to the EOC microenviron-
ment [47–49]. It is also plausible that more direct
tumor-promoting actions could be imposed by specific
infectious agents. A range of viral oncogenes can incap-
acitate key host proteins, enabling immune evasion, in-
hibition of apoptosis, and uncontrollable cell division
[50, 51]. However, bacteria involved in PID can display
similar effects, as studies have demonstrated that Chla-
mydia trachomatis can downregulate the DNA damage
response and cause degradation of P53 [52, 53]. Fur-
thermore, a recent study found that Chlamydia tracho-
matis was associated with increased EOC risk [38].
Finally, some of the factors that reduce EOC risk, in-
cluding tubal ligation and hysterectomy, abrupt the
passage to the pelvic cavity. Thus, they could impede
microbiological invasion to the internal genitals and the
suspected site of the precursor STIC lesions in the tubal
fimbria. In this study, all EBV-positive samples were from
serous EOC subtypes. This could be coincidental, but it
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could also indicate that a potential association between
EOC and EBV infection is subtype specific.
Conclusion
A significantly higher prevalence of EBV DNA was de-
tected in EOC samples than in tissue samples from a be-
nign control group. EBV infection is a contributing factor
in other epithelial cancers, but more research is needed to
uncover the potential relation to EOC.
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